Meta-Analysis Evaluates Clinical Studies for Biosimilar Safety and Immunogenicity
Scientists from the Center for Drug Evaluation and Research (CDER) have undertaken a meta-analysis to assess the significance of comparative clinical studies (CCS) in establishing the biosimilarity of biologics. Biologics, which are typically large and complex molecules derived from natural sources, include therapeutic proteins such as monoclonal antibodies and fusion proteins. These products have revolutionized treatment options for various chronic diseases and cancers but are often costly and challenging to produce. The Biologics Price Competition and Innovation Act of 2009 (BPCI Act) created a pathway for the approval of biosimilars, requiring that these products demonstrate high similarity to an FDA-approved reference product without clinically meaningful differences in safety or effectiveness. To support this demonstration, both analytical similarity studies and clinical studies are usually conducted. Historically, clinical development for biosimilars has included CCS to confirm the absence of significant differences between the proposed biosimilar and the reference product. However, recent findings indicate that pharmacokinetic (PK) studies, which compare the exposure levels of the biosimilar and reference product, may offer comparable insights regarding safety and immunogenicity, potentially alleviating the need for extensive CCS. The meta-analysis reviewed data from 35 approved biosimilars, focusing on the additional information provided by CCS in comparison to PK studies. The results revealed that CCS, which involve extensive patient trials, are costly and may not be as effective in detecting differences between products as previously thought. Instead, analytical studies that assess structural and functional characteristics of the biologics may provide more reliable evaluations of safety and efficacy. The CDER scientists highlighted that the findings from their meta-analysis support the notion that PK studies can adequately inform on immunogenicity and safety, suggesting that the regulatory framework could benefit from considering these insights when determining the necessity of CCS. This ongoing discourse on the role of clinical evidence in establishing biosimilarity is crucial for regulatory authorities and was recently addressed in a public workshop in fall 2023. The implications of these findings could lead to a more streamlined and cost-effective approach to biosimilar development, ultimately improving patient access to these essential therapies.




